Short answer
Editas Medicine, Inc. (EDIT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M (up 37.4% year over year) with net income of −$23M.
Q3 2026 key financials · XBRL
- Revenue
- $10M
- +37.4% YoY · −12.8% QoQ
- Net income
- −$23M
- +6.9% YoY · −28.3% QoQ
- Operating margin
- -234.3%
- EPS (diluted)
- −$0.14
- +46.2% YoY · +0.0% QoQ
Source: XBRL data from the Editas Medicine, Inc. (EDIT) Q3 2026 10-Q on SEC EDGAR. USD.
Editas Medicine, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $10.4M, up $2.8M from $7.5M YoY, driven by strategic-partner clinical milestones
- Net loss $23.4M vs $25.1M YoY, with operating expenses $34.6M vs $32.1M
- Research and development $21.2M, up $1.4M YoY, driven by $3.6M higher sublicense and license fees
- Cash, equivalents, and marketable securities $190.2M; operating cash outflow $73.8M through nine months
- EDIT-401 dosing on track for 2026; initial safety data expected first quarter 2027, cash runway into second half of 2028
Risk Factors
- No updated Risk Factors text provided, so no newly added quarterly risk identified
- Liquidity risk: accumulated deficit $1.7 billion and substantial additional capital required despite $190.2 million in cash, equivalents, and marketable securities
- Regulatory and legal risk: Cas9-I patent license disputes require $10.8 million reimbursement payments year-to-date
- Operational risk: gene-editing programs depend on successful clinical development, regulatory approval, manufacturing, and commercialization
- Financial risk: DRI revenue-sale liability $56.8 million, with estimated effective interest rate 7.7%
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Editas Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.